193 Results for "

regression

" in MedChemExpress (MCE) Product Catalog:
Products (193)

193 Results for "regression" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-16231
CAS No.: 501010-06-6
Synonyms: GGTI-2418
Target:  

Apoptosis

Research Areas:  

Cancer

Camprenstat (GGTI-2418) is a highly potent, competitive, and selective geranylgeranyltransferase I (GGTase I) inhibitor. Camprenstat inhibits GGTase I and FTase activities with IC50s of 9.5 nM and 53 μM, respectively. Camprenstat also increases p27(Kip1) and induces significant regression of breast tumors .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-148813
CAS No.: 2984506-77-4
Purity:  99.73%
Target:  

PROTACs STAT

Research Areas:  

Cancer

AK-2292 is a potent and selective STAT5 PROTAC degrader, with a DC50 of 0.10 μM. AK-2292 induces degradation of STAT5A/B proteins in vitro and in vivo. AK-2292 can induce tumor regression in acute myeloid leukemia and chronic myeloid leukemia xenograft mouse models . AK-2292 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-158105
CAS No.: 2851885-95-3
Purity:  99.43%
Target:  

PROTACs BCL6 CD20 IFNAR

Research Areas:  

Cancer

ARV-393 is a BCL6 PROTAC degrader. ARV-393 forms a complex with BCL6 and Cereblon, induces BCL6 ubiquitination, and mediates BCL6 degradation via the ubiquitin-proteasome system. ARV-393 enhances CD20 expression, interferon pathway activity and antigen presentation. ARV-393 induces tumor growth inhibition and regression. ARV-393 can be used in research related to non-Hodgkin's lymphoma, high-grade B-cell lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma and follicular lymphoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-156681
CAS No.: 2883540-92-7
Purity:  99.63%
Synonyms: STX-478; STX-478-101; LY4064809
Target:  

PI3K

Research Areas:  

Cancer

STX-478 (compound 80) is an oral CNS-penetrant allosteric mutant-selective PI3Kα inhibitor. STX-478 shows robust and durable tumor regression and can be used in cancer research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-147250
CAS No.: 2549174-42-5
Purity:  99.67%
Synonyms: RLY-4008
Target:  

FGFR

Research Areas:  

Cancer

Lirafugratinib (RLY-4008) is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib covalently binds to Cys491. Lirafugratinib targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-148029
CAS No.: 2553413-93-5
Purity:  98.16%
Synonyms: TAK-676
Target:  

STING

Research Areas:  

Cancer

Dazostinag disodium (TAK-676) is an agonist of STING, triggering the activation of STING signaling pathway and type I interferons. Dazostinag disodium is also a modulator of immune system, resulting complete regressions and durable memory T-cell immunity. Dazostinag disodium promotes durable IFN-dependent antitumor immunity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-161952
CAS No.: 2245082-05-5
Synonyms: JAB-3312
Target:  

SHP2

Research Areas:  

Cancer

Sitneprotafib (JAB-3312) is an orally effective anticancer phosphatase SHP2 inhibitor (IC50: 1.9 nM) with anti-cancer activity. Sitneprotafib has good tolerability and significantly induced tumor regression in a KYSE-520 mouse xenograft model .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-147250A
CAS No.: 2688040-45-9
Purity:  98.96%
Synonyms: RLY-4008 hydrochloride
Target:  

FGFR

Research Areas:  

Cancer

Lirafugratinib (RLY-4008) hydrochloride is an orally active, irreversible and highly selective FGFR2 inhibitor with an IC50 of 3 nM. Lirafugratinib hydrochloride covalently binds to Cys491. Lirafugratinib hydrochloride targets FGFR2 primary alterations and resistance mutations and induces tumor regression while sparing other FGFRs .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-136447
CAS No.: 1640294-30-9
Purity:  99.32%
Target:  

AMPK

Research Areas:  

Cancer

ASP4132 is an orally active, potent AMPK activator with an EC50 of 18 nM. ASP4132 has anti-cancer activity and makes tumor regression in breast cancer xenograft mouse models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-155537
CAS No.: 2064269-82-3
Purity:  99.50%
Synonyms: YK-029A
Target:  

EGFR

Research Areas:  

Cancer

YK-029A is an orally active inhibitor of mutant EGFR,targeting to both the T790M mutations (EGFR T790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity,and results tumor regression in EGFRex20ins-driven PDX models .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-119257
CAS No.: 450839-40-4
Purity:  98.18%
Research Areas:  

Cancer

ABT-100, a chemical probe, is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC50s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-157229
CAS No.: 2765525-82-2
Purity:  98.25%
Target:  

EGFR ERK

Research Areas:  

Cancer

STX-721 is an orally active, irreversible, covalent EGFR exon 20 insertion (ex20ins) inhibitor that selectively targets ex20ins-mutant dynamic protein states. STX-721 potently inhibits the kinase activity of EGFR ex20ins mutants (NPG, ASV, SVD). STX-721 inhibits phosphorylation of EGFR (pEGFR Y1068) and downstream ERK (pERK Thr202/Tyr204), and suppresses proliferation of ex20ins-mutant Ba/F3 cells and human NSCLC cell lines (NCI-H2073 ASV KI, CUTO-14 ASV). STX-721 induces tumor regression in EGFR ex20ins-mutant PDX/CDX models. STX-721 can be used for the study of non-small cell lung cancer (NSCLC) harboring EGFR or HER2 ex20ins mutations .
loading...
    loading...
Cat. No.: HY-157228
CAS No.: 2938169-76-5
Purity:  99.47%
Target:  

PROTACs Ras

Research Areas:  

Cancer

ACBI3 (compound 7), a chemical probe, is a PROTAC targeting KRAS. ACBI3 achieves in vivo degradation of oncogenic KRAS, resulting in durable pathway modulation and tumor regressions in KRAS mutant xenograft mouse models .
loading...
    loading...
Cat. No.: HY-175749
CAS No.: 3025467-07-3
Target:  

Molecular Glues Wee1

Research Areas:  

Inflammation/Immunology Cancer

BMS-986463, a CRBN E3 ligase modulator (CELMoD), is a WEE1 kinase molecular glue degrader. BMS-986463 significantly inhibits tumor regression and reduces the level of phospho-CDK2. BMS-986463 can be used for advanced malignant solid tumors like non-small cell lung cancer (NSCLC) research .
loading...
    loading...
Cat. No.: HY-141523
CAS No.: 2172652-48-9
Purity:  99.70%
Synonyms: RMC-4630; SHP2-IN-7
Target:  

SHP2 Phosphatase

Research Areas:  

Cancer

Vociprotafib (RMC-4630) is an orally active, selective and potent phosphatase SHP2 inhibitor, which blocks activation of the RAS-RAF-MEK-ERK signaling pathway with antitumor activity. Vociprotafib accelerates the time to, and increases the magnitude of, tumor regressions in Osimertinib (HY-15772)-sensitive EGFR-mutant tumors of mice .
loading...
    loading...
Cat. No.: HY-P9933
CAS No.: 1363687-32-4
Synonyms: APN-311; Ch14.18; MAb-14.18

Target:  

Apoptosis PERK mTOR

Research Areas:  

Cancer

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer .
loading...
    loading...
Cat. No.: HY-17449
CAS No.: 168555-66-6
Synonyms: CA 4DP; CA 4P; Combretastatin A4 disodium phosphate
Fosbretabulin disodium (CA 4DP) is a tubulin destabilizing agent. Fosbretabulin disodium is the Combretastatin A4 proagent that selectively targets endothelial cells, induces regression of nascent tumour neovessels, reduces tumour blood flow and causes central tumour necrosis .
loading...
    loading...
Cat. No.: HY-P99948
CAS No.: 2329692-74-0
Synonyms: AMG-596

Target:  

EGFR CD3

Research Areas:  

Neurological Disease Cancer

Etevritamab (AMG-596) is a bispecific T-cell engager that targets EGFRvIII and CD3. Etevritamab simultaneously binds CD3 on T cells and EGFRvIII on glioblastoma multiforme cells, thereby forming a bridge structure. Etevritamab triggers T-cell activation, proliferation, secretion of cytotoxic substances, and tumor cell lysis. Etevritamab extends overall survival and induces tumor regression in mouse models of glioblastoma multiforme. Etevritamab can be used for research related to glioblastoma .
loading...
    loading...
Cat. No.: HY-114440
CAS No.: 1980787-47-0
Purity:  98.94%
Synonyms: GR-MD-02
Target:  

Galectin Apoptosis

Research Areas:  

Cancer

Belapectin (GR-MD-02) is a Galectin-3 (Gal-3) inhibitor. Belapectin drives tumor-induced immunosuppression by inducing T cell Apoptosis. Belapectin promotes tumor regression and improves survival of tumor-bearing mice through a CD8+ T cell-dependent mechanism. Belapectin binds to Gal-3 with affinity Ki of 2.8 μM .
loading...
    loading...